Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methotrexate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR known ✓ | P00374 | 4/20 | 0.98 |
| ▸ | FPGS | Q05932 | 3/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | TLR4 | O00206 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | TYMS | P04818 | 1/20 | 0.98 |
| ▸ | GLA | P06280 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 1/20 | 0.98 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.98 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.98 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.98 |
| ▸ | GART | P22102 | 1/20 | 0.98 |
| ▸ | APEX1 | P27695 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methotrexate SCHEMBL4136 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL11175892 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL406878 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL5307856 | 1.00 | DHFR (0.98) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL171251 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL2301949 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL3711 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL20548444 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL8216266 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 | |
| Methotrexate SCHEMBL16013534 | 0.99 | DHFR (1.00) | DHFRFPGSKDM4ETLR4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075790-A | Drug-loaded polypyrrole interdigital microelectrode and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-119770703-A | Thermosensitive liquid embolic agent, preparation method thereof and thermosensitive composite embolic agent | 科睿驰（深圳）医疗科技发展有限公司 | 2025-04-08 | — | — | CN | claimed |
| US-20250041216-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2025-02-06 | — | — | US | claimed |
| US-11969503-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2024-04-30 | — | — | US | claimed |
| US-20230233464-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2023-07-27 | — | — | US | claimed |
| US-20210401742-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2021-12-30 | — | — | US | claimed |
| US-11116724-B2 | Methotrexate composition | Rosemount Pharmaceuticals Ltd (GB) | 2021-09-14 | — | — | US | claimed |
| CN-108451931-B | PAH/F polyelectrolyte compound nano-carrier and preparation method thereof | 华侨大学 | 2021-04-30 | — | — | CN | claimed |
| US-20200237664-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2020-07-30 | — | — | US | claimed |
| US-10610485-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2020-04-07 | — | — | US | claimed |
| US-9855215-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2018-01-02 | — | — | US | claimed |
| US-20160151281-A1 | Methotrexate Composition | ROSEMONT PHARMACEUTICALS LTD. (GB) | 2016-06-02 | — | — | US | claimed |
| US-9259427-B2 | Methotrexate composition | ROSEMONT PHARMACEUTICALS LTD (GB) | 2016-02-16 | — | — | US | claimed |
| EP-2614814-A1 | Methotrexate composition | Rosemont Pharmaceuticals Ltd (GB) | 2013-07-17 | — | — | EP | claimed |
| US-20130178476-A1 | METHOTREXATE COMPOSITION | ROSEMONT PHARMACEUTICALS LTD (GB) | 2013-07-11 | — | — | US | claimed |
| US-7901453-B2 | Coated implantable medical device | COOK INCORPORATED (US) | 2011-03-08 | — | — | US | claimed |
| US-20080145399-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | COOK MEDICAL TECHNOLOGIES LLC | 2008-06-19 | — | — | US | claimed |
| US-20080145398-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | claimed |
| US-20050101605-A1 | Oral liquid formulations of methotrexate | DURAMED PHARMACEUTICALS, INC. | 2005-05-12 | — | — | US | claimed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101605-A1 | Oral liquid formulations of methotrexate | MTX2, MTX1, DHFR | DHFR 3/4885FPGS 10/4885KDM4E 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.